Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)
Market Cap | 160.848 Million | Shares Outstanding | 154.661 Million | Avg 30-day Volume | 783.715 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.12 |
Price to Revenue | 2.5316 | Debt to Equity | 0.0 | EBITDA | -105.584 Million |
Price to Book Value | 2.1482 | Operating Margin | -157.8217 | Enterprise Value | 14.629 Million |
Current Ratio | 3.359 | EPS Growth | 0.333 | Quick Ratio | 2.629 |
1 Yr BETA | 0.9797 | 52-week High/Low | 2.65 / 1.0 | Profit Margin | -160.3886 |
Operating Cash Flow Growth | -4446.2692 | Altman Z-Score | -4.3128 | Free Cash Flow to Firm | -138.163 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-06-01 | 1 | |
|
0 | 2023-06-01 | 2 | |
|
0 | 2023-06-01 | 1 | |
PICCINA CINTIA CHIEF COMMERCIAL OFFICER |
|
19,535 | 2023-01-31 | 3 |
BERTRAND WILLIAM C JR CHIEF OPERATING OFFICER |
|
7,264 | 2023-01-17 | 4 |
RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER |
|
13,351 | 2023-01-17 | 6 |
WOOD GAVIN CHIEF FINANCIAL OFFICER |
|
1,915,056 | 2023-01-17 | 1 |
TAYTON-MARTIN HELEN KATRINA CHIEF BUSINESS & STRGY OFFICER |
|
1,918,392 | 2023-01-17 | 1 |
LUNGER JOHN CHIEF PATIENT SUPPLY OFFICER |
|
7,264 | 2023-01-17 | 6 |
NORRY ELLIOT CHIEF MEDICAL OFFICER |
|
3,491 | 2023-01-17 | 4 |
BREWER JOANNA ELIZABETH CHIEF SCIENTIFIC OFFICER |
|
1,856,808 | 2023-01-17 | 1 |
|
1,000,439 | 2022-07-01 | 1 | |
|
500,000 | 2022-07-01 | 1 | |
|
710,711 | 2022-07-01 | 1 | |
|
816,067 | 2022-07-01 | 1 | |
|
737,050 | 2022-07-01 | 1 | |
|
737,050 | 2022-07-01 | 1 | |
|
500,000 | 2022-07-01 | 1 | |
|
500,000 | 2022-07-01 | 1 | |
|
102,478,668 | 2020-01-24 | 0 | |
|
102,478,668 | 2020-01-24 | 0 | |
|
102,478,668 | 2020-01-24 | 0 | |
|
102,478,668 | 2020-01-24 | 0 | |
GARONE MICHAEL INTERIM CFO |
|
0 | 2019-10-01 | 0 |
AMADO RAFAEL PRESIDENT, R&D |
|
17,237 | 2019-08-06 | 0 |
|
0 | 2019-07-02 | 0 | |
BINDER-SCHOLL GWENDOLYN KNOWLTON CHIEF TECHNOLOGY OFFICER |
|
2,487 | 2019-01-14 | 0 |
|
94,978,668 | 2018-09-07 | 0 | |
|
82,978,668 | 2018-09-07 | 0 | |
|
82,978,668 | 2018-09-07 | 0 | |
|
94,978,668 | 2018-09-07 | 0 | |
|
82,978,668 | 2018-09-07 | 0 | |
|
4,901,310 | 2018-06-04 | 0 | |
|
4,901,310 | 2018-06-04 | 0 | |
|
6,149,377 | 2017-03-27 | 0 | |
|
0 | 2016-08-11 | 0 | |
|
0 | 2016-08-11 | 0 | |
|
59,269,000 | 2016-01-01 | 0 | |
|
59,269,000 | 2016-01-01 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MENZEL GARRY E - Director see footnote |
2023-06-01 16:59:07 -0400 | 2023-06-01 | A | 200,646 | a | 200,646 | indirect | -3.7037 | 0.0 | 1 | -3.7037 | 2 | ||||
MENZEL GARRY E - Director see footnote |
2023-06-01 16:59:07 -0400 | 2023-06-01 | A | 200,647 | a | 200,647 | indirect | -3.7037 | 0.0 | 1 | -3.7037 | 2 | ||||
2023-06-01 16:59:07 -0400 | 2023-06-01 | A | 209,931 | a | 209,931 | direct | -3.7037 | 0.0 | 1 | -3.7037 | 2 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 22:15:03 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 21:45:05 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 21:15:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 20:45:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 20:15:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 19:45:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 19:15:03 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 18:45:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 18:15:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 17:45:04 UTC | -0.9658 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 17:15:04 UTC | -0.9658 | 6.0358 | 8400000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 16:45:04 UTC | -0.9758 | 6.0358 | 8400000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 16:15:03 UTC | -0.9758 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 15:45:04 UTC | -0.9758 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 15:15:04 UTC | -0.9758 | 6.0358 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 14:45:04 UTC | -1.7001 | 6.7601 | 7600000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 14:15:03 UTC | -1.7001 | 6.7601 | 8400000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 13:45:03 UTC | -1.7001 | 6.7601 | 8400000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 13:15:03 UTC | -1.7001 | 6.7601 | 8400000 |
ADAPTIMMUNE THERAPEUTICS-ADR ADAP | 2023-06-06 12:45:05 UTC | -1.7001 | 6.7601 | 8400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ADAP | -9000.0 shares, $-9810.0 | 2023-03-31 | N-PORT |